Ravindra Kumar Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Ravindra Kumar.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Ravindra Kumar. Ravindra Kumar is SVP & Chief Scientific Officer in ACCELERON PHARMA INC ($XLRN) and VP & Chief Scientific Officer in ACCELERON PHARMA INC ($XLRN).
Latest Insider Trading Transactions of Ravindra Kumar
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 10 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 45.24 | 3,389 | 153,318 | 86,986 | 90.4 K to 87 K (-3.75 %) |
| Sep 10 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 45.24 | 3,389 | 153,318 | 86,986 | 90.4 K to 87 K (-3.75 %) |
| Apr 11 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 44.24 | 70 | 3,097 | 90,375 | 90.4 K to 90.4 K (-0.08 %) |
| Apr 11 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 45.46 | 100 | 4,546 | 90,445 | 90.5 K to 90.4 K (-0.11 %) |
| Apr 11 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 44.62 | 3,452 | 154,028 | 90,545 | 94 K to 90.5 K (-3.67 %) |
| Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | A | 41.64 | 21,500 | 895,260 | 21,500 | |
| Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Grant | A | 0.00 | 3,850 | 0 | 93,997 | 90.1 K to 94 K (+4.27 %) |
| Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 43.94 | 374 | 16,434 | 90,147 | 90.5 K to 90.1 K (-0.41 %) |
| Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 43.20 | 3,051 | 131,803 | 90,521 | 93.6 K to 90.5 K (-3.26 %) |
| Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 42.45 | 2,363 | 100,309 | 93,572 | 95.9 K to 93.6 K (-2.46 %) |
| Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 39.16 | 100 | 3,916 | 95,935 | 96 K to 95.9 K (-0.10 %) |
| Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 38.34 | 1,103 | 42,289 | 96,035 | 97.1 K to 96 K (-1.14 %) |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | A | 40.61 | 26,775 | 1,087,333 | 26,775 | |
| Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Grant | A | 0.00 | 4,463 | 0 | 97,138 | 92.7 K to 97.1 K (+4.82 %) |
| Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 42.41 | 4,300 | 182,363 | 92,675 | 97 K to 92.7 K (-4.43 %) |
| Sep 29 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 5.28 | 6,761 | 35,698 | 0 | |
| Sep 29 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 5.28 | 6,761 | 35,698 | 96,975 | 90.2 K to 97 K (+7.49 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 38.12 | 8 | 305 | 90,214 | 90.2 K to 90.2 K (-0.01 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 39.39 | 500 | 19,695 | 90,222 | 90.7 K to 90.2 K (-0.55 %) |
| Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 38.31 | 4,605 | 176,418 | 90,722 | 95.3 K to 90.7 K (-4.83 %) |
| Aug 09 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 24.11 | 13,065 | 314,997 | 3,624 | |
| Aug 09 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 35.41 | 13,065 | 462,632 | 95,327 | 108.4 K to 95.3 K (-12.05 %) |
| Aug 09 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 24.11 | 13,065 | 314,997 | 108,392 | 95.3 K to 108.4 K (+13.71 %) |
| Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 7.12 | 937 | 6,671 | 0 | |
| Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 32.00 | 937 | 29,984 | 95,327 | 96.3 K to 95.3 K (-0.97 %) |
| Jul 07 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 7.12 | 937 | 6,671 | 96,264 | 95.3 K to 96.3 K (+0.98 %) |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | A | 30.17 | 41,300 | 1,246,021 | 41,300 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Grant | A | 0.00 | 6,900 | 0 | 95,327 | 88.4 K to 95.3 K (+7.80 %) |
| Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 27.60 | 1,641 | 45,292 | 88,427 | 90.1 K to 88.4 K (-1.82 %) |
| Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 26.81 | 359 | 9,625 | 90,068 | 90.4 K to 90.1 K (-0.40 %) |
| Dec 23 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 3.88 | 4,561 | 17,697 | 0 | |
| Dec 23 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 5.28 | 10,000 | 52,800 | 6,761 | |
| Dec 23 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 3.88 | 4,561 | 17,697 | 90,427 | 85.9 K to 90.4 K (+5.31 %) |
| Dec 23 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 5.28 | 10,000 | 52,800 | 85,866 | 75.9 K to 85.9 K (+13.18 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 27.97 | 4,550 | 127,264 | 31,850 | |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 24.11 | 8,101 | 195,315 | 16,689 | |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 7.12 | 4,182 | 29,776 | 937 | |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 24.11 | 4,210 | 101,503 | 24,790 | |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 7.12 | 2,381 | 16,953 | 5,119 | |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 5.28 | 1,115 | 5,887 | 16,761 | |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 5.28 | 10,984 | 57,996 | 0 | |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 3.88 | 954 | 3,702 | 4,561 | |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | M | 5.28 | 7,124 | 37,615 | 17,876 | |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 34.14 | 16,833 | 574,679 | 75,866 | 92.7 K to 75.9 K (-18.16 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 27.97 | 4,550 | 127,264 | 92,699 | 88.1 K to 92.7 K (+5.16 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 24.11 | 8,101 | 195,315 | 88,149 | 80 K to 88.1 K (+10.12 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 7.12 | 4,182 | 29,776 | 80,048 | 75.9 K to 80 K (+5.51 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 34.00 | 28 | 952 | 75,866 | 75.9 K to 75.9 K (-0.04 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 33.37 | 19,616 | 654,586 | 75,894 | 95.5 K to 75.9 K (-20.54 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 24.11 | 4,210 | 101,503 | 95,510 | 91.3 K to 95.5 K (+4.61 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 7.12 | 2,381 | 16,953 | 91,300 | 88.9 K to 91.3 K (+2.68 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 5.28 | 1,115 | 5,887 | 88,919 | 87.8 K to 88.9 K (+1.27 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 5.28 | 10,984 | 57,996 | 87,804 | 76.8 K to 87.8 K (+14.30 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 3.88 | 954 | 3,702 | 76,820 | 75.9 K to 76.8 K (+1.26 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 34.98 | 1,561 | 54,604 | 75,866 | 77.4 K to 75.9 K (-2.02 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Sell | S | 34.31 | 14,448 | 495,711 | 77,427 | 91.9 K to 77.4 K (-15.73 %) |
| Oct 11 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Buy | M | 5.28 | 7,124 | 37,615 | 91,875 | 84.8 K to 91.9 K (+8.41 %) |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | A | 27.97 | 36,400 | 1,018,108 | 36,400 | |
| Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Grant | A | 0.00 | 6,000 | 0 | 84,751 | 78.8 K to 84.8 K (+7.62 %) |
| Feb 29 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 3.88 | 8,000 | 31,040 | 5,515 | |
| Feb 29 2016 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 3.88 | 8,000 | 31,040 | 78,751 | 70.8 K to 78.8 K (+11.31 %) |
| Oct 21 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.28 | 5,516 | 29,124 | 10,984 | |
| Oct 21 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.08 | 6,250 | 31,750 | 0 | |
| Oct 21 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 1.80 | 2,300 | 4,140 | 0 | |
| Oct 21 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.28 | 5,516 | 29,124 | 70,751 | 65.2 K to 70.8 K (+8.46 %) |
| Oct 21 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.08 | 6,250 | 31,750 | 65,235 | 59 K to 65.2 K (+10.60 %) |
| Oct 21 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 1.80 | 2,300 | 4,140 | 58,985 | 56.7 K to 59 K (+4.06 %) |
| Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 3.88 | 11,485 | 44,562 | 13,515 | |
| Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 35.00 | 33,000 | 1,155,000 | 56,685 | 89.7 K to 56.7 K (-36.80 %) |
| Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 3.88 | 11,485 | 44,562 | 89,685 | 78.2 K to 89.7 K (+14.69 %) |
| Sep 11 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Grant | A | 0.00 | 40,000 | 0 | 78,200 | 38.2 K to 78.2 K (+104.71 %) |
| Apr 30 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 1.80 | 5,000 | 9,000 | 2,300 | |
| Apr 30 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 1.80 | 5,000 | 9,000 | 38,200 | 33.2 K to 38.2 K (+15.06 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 3,500 | 20,580 | 0 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 500 | 2,940 | 0 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 42.04 | 100 | 4,204 | 33,200 | 33.3 K to 33.2 K (-0.30 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 41.09 | 366 | 15,039 | 33,300 | 33.7 K to 33.3 K (-1.09 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 40.62 | 1,034 | 42,001 | 33,666 | 34.7 K to 33.7 K (-2.98 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 42.06 | 300 | 12,618 | 34,700 | 35 K to 34.7 K (-0.86 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 41.22 | 1,614 | 66,529 | 35,000 | 36.6 K to 35 K (-4.41 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 40.56 | 2,086 | 84,608 | 36,614 | 38.7 K to 36.6 K (-5.39 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 3,500 | 20,580 | 38,700 | 35.2 K to 38.7 K (+9.94 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 500 | 2,940 | 35,200 | 34.7 K to 35.2 K (+1.44 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 4,000 | 23,520 | 500 | |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 39.46 | 300 | 11,838 | 34,700 | 35 K to 34.7 K (-0.86 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 38.56 | 1,200 | 46,272 | 35,000 | 36.2 K to 35 K (-3.31 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 39.13 | 1,435 | 56,152 | 36,200 | 37.6 K to 36.2 K (-3.81 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 38.39 | 2,565 | 98,470 | 37,635 | 40.2 K to 37.6 K (-6.38 %) |
| Feb 04 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 4,000 | 23,520 | 40,200 | 36.2 K to 40.2 K (+11.05 %) |
| Jan 13 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 41.06 | 1,100 | 45,166 | 36,200 | 37.3 K to 36.2 K (-2.95 %) |
| Jan 13 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 40.09 | 400 | 16,036 | 37,300 | 37.7 K to 37.3 K (-1.06 %) |
| Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | A | 41.20 | 41,000 | 1,689,200 | 41,000 | |
| Jan 05 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 4,000 | 23,520 | 4,500 | |
| Jan 05 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 39.37 | 400 | 15,748 | 37,700 | 38.1 K to 37.7 K (-1.05 %) |
| Jan 05 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 38.36 | 3,600 | 138,096 | 38,100 | 41.7 K to 38.1 K (-8.63 %) |
| Jan 05 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 4,000 | 23,520 | 41,700 | 37.7 K to 41.7 K (+10.61 %) |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 1.80 | 5,825 | 10,485 | 7,300 | |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 0.92 | 3,985 | 3,666 | 0 | |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 1.80 | 5,825 | 10,485 | 37,700 | 31.9 K to 37.7 K (+18.27 %) |
| Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 0.92 | 3,985 | 3,666 | 31,875 | 27.9 K to 31.9 K (+14.29 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 4,000 | 23,520 | 8,500 | |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 37.44 | 1,100 | 41,184 | 27,890 | 29 K to 27.9 K (-3.79 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 36.10 | 1,000 | 36,100 | 28,990 | 30 K to 29 K (-3.33 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 34.87 | 1,900 | 66,253 | 29,990 | 31.9 K to 30 K (-5.96 %) |
| Dec 02 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 4,000 | 23,520 | 31,890 | 27.9 K to 31.9 K (+14.34 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.28 | 5,000 | 26,400 | 16,500 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 5,000 | 29,400 | 1,500 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 4,000 | 23,520 | 14,500 | |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 35.00 | 12,000 | 420,000 | 27,890 | 39.9 K to 27.9 K (-30.08 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.28 | 5,000 | 26,400 | 39,890 | 34.9 K to 39.9 K (+14.33 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 5,000 | 29,400 | 34,890 | 29.9 K to 34.9 K (+16.73 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 33.56 | 2,400 | 80,544 | 29,890 | 32.3 K to 29.9 K (-7.43 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 32.46 | 1,600 | 51,936 | 32,290 | 33.9 K to 32.3 K (-4.72 %) |
| Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 4,000 | 23,520 | 33,890 | 29.9 K to 33.9 K (+13.38 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 4,000 | 23,520 | 18,500 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.28 | 3,500 | 18,480 | 21,500 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 1,500 | 8,820 | 6,500 | |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 30.36 | 608 | 18,459 | 29,890 | 30.5 K to 29.9 K (-1.99 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 29.57 | 3,392 | 100,301 | 30,498 | 33.9 K to 30.5 K (-10.01 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 4,000 | 23,520 | 33,890 | 29.9 K to 33.9 K (+13.38 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 30.00 | 7,000 | 210,000 | 29,890 | 36.9 K to 29.9 K (-18.98 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.28 | 3,500 | 18,480 | 36,890 | 33.4 K to 36.9 K (+10.48 %) |
| Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 1,500 | 8,820 | 33,390 | 31.9 K to 33.4 K (+4.70 %) |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 2,000 | 11,760 | 8,000 | |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 26.40 | 2,000 | 52,800 | 31,890 | 33.9 K to 31.9 K (-5.90 %) |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 2,000 | 11,760 | 33,890 | 31.9 K to 33.9 K (+6.27 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 5,000 | 29,400 | 10,000 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 30.00 | 7,000 | 210,000 | 31,890 | 38.9 K to 31.9 K (-18.00 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 5,000 | 29,400 | 38,890 | 33.9 K to 38.9 K (+14.75 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 29.85 | 2,000 | 59,700 | 33,890 | 35.9 K to 33.9 K (-5.57 %) |
| Jul 02 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 34.10 | 2,000 | 68,200 | 35,890 | 37.9 K to 35.9 K (-5.28 %) |
| Jun 24 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 5,000 | 29,400 | 15,000 | |
| Jun 24 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 35.00 | 7,000 | 245,000 | 37,890 | 44.9 K to 37.9 K (-15.59 %) |
| Jun 24 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 5,000 | 29,400 | 44,890 | 39.9 K to 44.9 K (+12.53 %) |
| Jun 04 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 29.72 | 2,000 | 59,440 | 39,890 | 41.9 K to 39.9 K (-4.77 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 5,000 | 29,400 | 20,000 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 32.27 | 200 | 6,454 | 41,890 | 42.1 K to 41.9 K (-0.48 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 31.51 | 1,800 | 56,718 | 42,090 | 43.9 K to 42.1 K (-4.10 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 32.13 | 500 | 16,065 | 43,890 | 44.4 K to 43.9 K (-1.13 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 31.23 | 6,500 | 202,995 | 44,390 | 50.9 K to 44.4 K (-12.77 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 5,000 | 29,400 | 50,890 | 45.9 K to 50.9 K (+10.90 %) |
| Apr 24 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 35.86 | 2,000 | 71,720 | 45,890 | 47.9 K to 45.9 K (-4.18 %) |
| Dec 09 2013 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | A | 24.11 | 29,000 | 699,190 | 29,000 |
Page: 1